CRISPR Therapeutics AGCRSP
Market cap
$5B
P/E ratio
| Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | |
| Collaboration Revenue | - | - | - | - | 1 | 913 | 0 | 370 | 35 |
| Grant | - | - | - | - | 0 | 2 | 1 | 1 | 2 |
| Total revenue | - | - | - | - | 1 | 915 | 1 | 371 | 37 |
| Research and development | 42 | 70 | 114 | 179 | 267 | 439 | 462 | 387 | 321 |
| General and administrative | 31 | 36 | 48 | 63 | 88 | 103 | 102 | 76 | 73 |
| Collaboration Expense | - | - | - | - | - | - | 110 | 130 | 110 |
| Total operating expenses | 73 | 106 | 162 | 243 | 355 | 541 | 674 | 594 | 504 |
| Loss from operations | -68 | -65 | -159 | 47 | -354 | 374 | -673 | -223 | -467 |
| Other income, net | 79 | -0 | -1 | 26 | 6 | 6 | 23 | 72 | 104 |
| Total other income, net | 45 | -2 | -5 | 21 | 6 | 6 | 23 | 72 | 104 |
| Net loss before income taxes | -23 | -67 | -164 | 67 | -348 | 380 | -650 | -151 | -363 |
| (Provision) benefit for income taxes | 0 | 2 | 1 | 0 | 1 | 2 | -0 | 3 | 4 |
| Net loss | -23 | -68 | -165 | 67 | -349 | 378 | -650 | -154 | -366 |
| Foreign currency translation adjustment | -0 | 0 | -0 | 0 | 0 | -0 | -0 | 0 | -0 |
| Unrealized (loss) gain on marketable securities | - | - | - | - | -0 | -5 | -10 | 17 | -0 |
| Comprehensive loss | -23 | -68 | -165 | 67 | -349 | 373 | -661 | -136 | -366 |
| Earnings Per Share, Basic | - | - | - | 1.23 | -5.29 | 4.97 | -8.36 | -1.94 | -4.34 |
| Earnings Per Share, Diluted | - | - | - | 1.17 | -5.29 | 4.7 | -8.36 | -1.94 | -4.34 |